Get the Stockscreener App
121.07
0.03%
-0.04
Haemonetics Corp stock is traded at $121.07, with a volume of 440.53K.
It is down -0.03% in the last 24 hours and up +14.00% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$121.11
Open:
$122.2
24h Volume:
440.53K
Relative Volume:
0.49
Market Cap:
$5.51B
Revenue:
$1.33B
Net Income/Loss:
$97.31M
P/E Ratio:
59.59
EPS:
2.0317
Net Cash Flow:
$260.44M
1W Performance:
+1.34%
1M Performance:
+14.00%
6M Performance:
+95.43%
1Y Performance:
+149.22%
1-Day Range:
$118.65
$122.46
1-Week Range:
$116.52
$123.77
52-Week Range:
$48.55
$123.77
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
121.07 | 5.51B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
104.80 | 181.34B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
95.48 | 122.13B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
292.16 | 112.06B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.09 | 63.90B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.14 | 50.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-26 | Upgrade | Citigroup | Neutral → Buy |
| May-22-26 | Upgrade | BofA Securities | Neutral → Buy |
| May-12-26 | Reiterated | Barrington Research | Outperform |
| Dec-15-25 | Downgrade | Needham | Buy → Hold |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade) - Seeking Alpha
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? - Zacks Investment Research
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? - Yahoo Finance
Haemonetics (HAE) Jumped, What Is Behind The Move? - Yahoo Finance
Haemonetics (HAE) Surges Over 17% on Plasma Supply Deal with CSL - GuruFocus
Haemonetics Corporation Stock 12‑Month Price Target Raised to $120, Implies 18% Upside - TradingView
Haemonetics advances 17% on CSL supply deal (HAE:NYSE) - Seeking Alpha
Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123 - Timothy Sykes
Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123 - StocksToTrade
Haemonetics (HAE) Shares Skyrocket, What You Need To Know - Yahoo Finance
Haemonetics (HAE) Surges 12.8% to $114.69 - AlphaStreet
Haemonetics Stock Climbs As Citi Hikes Price Target On CSL Upside - StocksToTrade
Haemonetics (HAE) Stock Climbs After Citi Ups Price Target - www.timothysykes.com
Haemonetics (HAE) Stock Climbs After Citi Ups Price Target - Timothy Sykes
Haemonetics Jumps to 52-Week High as CSL Plasma Plans Full U.S. Device Rollout by 2027 - finance.biggo.com
Haemonetics jumps after strong Q4 results and fiscal 2027 outlook - Quiver Quantitative
Haemonetics Stock Hits 52-Week HighHere's Why - Benzinga
Haemonetics Stock Hits 52-Week HighHere's Why - Benzinga
Haemonetics Stock Hits 52-Week HighHere's Why - TradingView
Haemonetics Says CSL Plasma to Complete Rollout of Products by End-2027 - marketscreener.com
Haemonetics Stock Pops As Citi Hikes Price Target To $123 - StocksToTrade
Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123 - Timothy Sykes
Why is Haemonetics stock surging today? - Investing.com
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices - Yahoo Finance
Haemonetics (HAE) Surges 12.8% to $114.69 - AlphaStreet
Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers - Yahoo Finance
Haemonetics stock hits 52-week high at 114.0 USD - Investing.com
BTIG raises Haemonetics stock price target on CSL Plasma deal - Investing.com
Why is Haemonetics stock surging today? - Investing.com
Haemonetics stock surges 17% on CSL Plasma supply deal update - Yahoo Finance
Haemonetics Shares Gain as CSL Targets Rollout of Company's Devices by End of 2027 - marketscreener.com
Haemonetics (HAE) Secures Supply Deal with CSL Plasma for NexSys PCS Devices - GuruFocus
Haemonetics stock surges 17% on CSL Plasma supply deal update - Investing.com
Haemonetics gains after update on CSL supply deal (HAE:NYSE) - Seeking Alpha
Haemonetics: Non‑exclusive CSL Plasma supply deal; rollout expected by end‑2027 - TradingView
A rollout to all current U.S. CSL plasma centers is anticipated for Haemonetics (HAE), subject to change. - Stock Titan
CSL Expands Relationship With Haemonetics Corporation - TradingView
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
Haemonetics Q1 2027 Earnings Call Transcript - Benzinga
BTIG reiterates Buy rating on Haemonetics with $84 target - scanx.trade
Haemonetics stock heads into November 5 results with key benchmarks - AD HOC NEWS
Haemonetics stock heads into November 5 results after earnings beat - AD HOC NEWS
Haemonetics Corporation (NYSE: HAE) Share Price, HAE Stock News, HAE Share Price & Updates - kalkine.ca
Haemonetics Corporation (HAE) Stock forecasts - Yahoo Finance Singapore
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo! Finance Canada
Haemonetics Corporation (HAE) Stock Forecasts - Yahoo Finance
Haemonetics sets Q2FY27 earnings release date for November 5 - scanx.trade
Haemonetics elects Martin Madaus to board of directors - scanx.trade
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):